Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus
Vildagliptin Induces beta-Cell Neogenesis and Improves the Lipid Profile in a Later Phase of Type 1 Diabetes
Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
Vildagliptin With Metformin Once-Daily Regimen-Insights From a Single-Center Analysis
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
Vildagliptin reduces cardiac ischemic-reperfusion injury in obese orchiectomized rats
Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus
Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin
Vildagliptin in the treatment of type 2 diabetes mellitus
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
Vildagliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Vildagliptin A Review of its Use in Type 2 Diabetes Mellitus
Vildagliptin in clinical practice: a review of literature
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study
Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial
Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats
Vildagliptin and Insulin Combinatorial Therapy Drug Safety Monitoring in Diabetic Rats
Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis
Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats